| Clinical activity and tolerability of SL-401 (Tagraxofusp): recombinant diphtheria toxin and interleukin-3 in hematologic malignancies O Alkharabsheh, AE Frankel Biomedicines 7 (1), 6, 2019 | 39 | 2019 |
| Metformin and angiogenesis in cancer-revisited J Kannarkatt, O Alkharabsheh, H Tokala, NV Dimitrov Oncology 91 (4), 179-184, 2016 | 28 | 2016 |
| Vitamin B12 deficiency presenting as pseudo-thrombotic microangiopathy: a case report and literature review Y Fahmawi, Y Campos, M Khushman, O Alkharabsheh, A Manne, ... Clinical Pharmacology: Advances and Applications, 127-131, 2019 | 26 | 2019 |
| The human microbiota in multiple myeloma and proteasome inhibitors O Alkharabsheh, MH Sidiqi, MA Aljama, MA Gertz, AE Frankel Acta Haematologica 143 (2), 118-123, 2020 | 22 | 2020 |
| An overview of the toxicities of checkpoint inhibitors in older patients with cancer O Alkharabsheh, P Kannarkatt, J Kannarkatt, L Karapetyan, HS Laird-Fick, ... Journal of Geriatric Oncology 9 (5), 451-458, 2018 | 19 | 2018 |
| Cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with Bruton tyrosine kinase inhibitor O Alkharabsheh, A Alsayed, DM Morlote, A Mehta Current Oncology 28 (1), 837-841, 2021 | 13 | 2021 |
| Prevalence of occult celiac disease in females with iron deficiency in the United States: an NHANES analysis A Abdalla, SM Saifullah, M Osman, R Baniya, S Sidahmed, J LaChance, ... Journal of Community Hospital Internal Medicine Perspectives 7 (6), 347-350, 2017 | 12 | 2017 |
| Clinical and hematological predictors of high-grade immune-related adverse events associated with immune checkpoint inhibitors A Manne, MS Mulekar, DE Escobar, A Alsayed, G Sharma, ... Journal of Clinical Medicine Research 13 (5), 268, 2021 | 8 | 2021 |
| Checkpoint inhibitors in multiple myeloma: intriguing potential and unfulfilled promises O Alkharabsheh, Z Trisel, S Badami, MA Aljama, MH Sidiqi Cancers 14 (1), 113, 2021 | 6 | 2021 |
| Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy OA Alkharabsheh, SS Saadeh, DL Zblewski, N Gangat, KH Begna, ... Annals of Hematology 98, 331-337, 2019 | 6 | 2019 |
| Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma AO Abdallah, Z Mahmoudjafari, N Ahmed, W Cui, L Shune, J McGuirk, ... European Journal of Haematology 110 (6), 626-632, 2023 | 5 | 2023 |
| Small molecule 20S proteasome enhancer regulates MYC protein stability and exhibits antitumor activity in multiple myeloma E Njomen, A Vanecek, TA Lansdell, YT Yang, PZ Schall, CM Harris, ... Biomedicines 10 (5), 938, 2022 | 5 | 2022 |
| The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma P Prodduturvar, W Mneimneh, V Dal Zotto, S Akbar, L Grimm, P Rider, ... Oncotarget 12 (15), 1490, 2021 | 3 | 2021 |
| Cemiplimab in advanced cutaneous squamous cell carcinoma: A real-world experience of outcomes and safety. S Badami, A Mazloom, JH Howard, JS Liles, O Alkharabsheh, BE Persing, ... Journal of Clinical Oncology 40 (16_suppl), e21545-e21545, 2022 | 2 | 2022 |
| Usefulness of restaging pelvis magnetic resonance imaging after neoadjuvant concurrent chemoradiotherapy in patients with locally advanced rectal cancer Y Fahmawi, C Smith, L Grimm, S Khullar, P Rider, J Hunter, G Iliff, ... Clinical Colorectal Cancer 19 (4), e281-e287, 2020 | 2 | 2020 |
| Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacy E Njomen, TA Lansdell, A Vanecek, V Benham, MP Bernard, YT Yang, ... bioRxiv, 2020.08. 24.265470, 2020 | 2 | 2020 |
| The pattern of mucin 5AC (MUC5AC) expression using immunohistochemistry and its prognostic significance in patients with pancreatic ductal adenocarcinoma. A Manne, W Mneimneh, O Elkadi, DE Escobar, J Coley, GB Guzman, ... Journal of Clinical Oncology 38 (15_suppl), e16756-e16756, 2020 | 2 | 2020 |
| Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes O Alkharabsheh, SS Saadeh, MS Patnaik, H Alkhateeb, N Gangat, ... American journal of hematology 93 (12), E398-E401, 2018 | 2 | 2018 |
| The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS O Alkharabsheh, A Al-Kali, S Saadeh, R He, D Viswanatha, P Greipp, ... American journal of hematology 93 (11), E355-E357, 2018 | 2 | 2018 |
| Survival rates of male breast cancer compared to female: A Surveillance, Epidemiology, and End Results (SEER) database analysis. R Mushtaq, M Shaik, S Mistry, OA Alkharabsheh, M Shaqfeh, ... Journal of Clinical Oncology 31 (15_suppl), 6567-6567, 2013 | 2 | 2013 |
